Preclinical Therapeutic Testing (In Vitro / In Vivo Models)

This contract involves preclinical testing of novel therapeutic agents, including immunotherapies and targeted drugs, utilizing melanoma cell lines, organoids, or animal models to generate efficacy and toxicity data. The work spans both in vitro and in vivo models, aiming to provide critical early-stage evaluation of treatments against melanoma. The contract is issued by the Department of the Army under the Department of Defense and is categorized as a subcontract opportunity with NAICS code 541711, which pertains to research and development in biotechnology. The solicitation for this contract was posted on May 21, 2026, with a response deadline of October 14, 2026. Specific details about the place of performance and points of contact are not provided. The research conducted under this contract is essential for advancing therapeutic strategies by ensuring safety and effectiveness before proceeding to clinical trials. This opportunity supports the ongoing efforts to develop innovative cancer treatments with the potential to improve patient outcomes.